Danae Delivanis, MD, Division of Endocrinology, Diabetes, Metabolism, and Nutrition at Mayo Clinic, discusses pembrolizumab-induced thyroiditis in patients with cancer.
Danae Delivanis, MD, Division of Endocrinology, Diabetes, Metabolism, and Nutrition at Mayo Clinic, discusses pembrolizumab-induced thyroiditis in patients with cancer.
A retrospective comprehensive study looked at 94 patients, all who received the immune checkpoint inhibitor pembrolizumab for the treatment of their cancer, to determine how many experienced the side effect of thyroiditis.
In the study, the incidence of any thyroid abnormality was as high as 15%, says Delivanis. Of the 14 patients that experienced thyroid abnormality there were 7 cases of thyroiditis, 4 cases of new-onset or subclinical hypothyroidism, and three cases of recurrent hypothyroidism that required adjustments in treatment.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More